Cost of treatment for multidrug-resistant tuberculosis in South Korea

Young Ae Kang, Yong Jun Choi, Young Jae Cho, Sang Min Lee, Chul Gyu Yoo, Young Whan Kim, Sung Koo Han, Young Soo Shim, Jae Joon Yim

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objective and background: Costs associated with multidrug-resistant tuberculosis (MDR-TB) are higher than those associated with drug-susceptible TB because of the higher prices of second-line anti-TB drugs, the prolonged duration of treatment, greater productivity loss and higher mortality. The aim of this study was to estimate the cost of treatment for MDR-TB according to the treatment strategy and prognosis in South Korea. Methods: We estimated the direct (medical and non-medical) and indirect cost for the treatment of MDR-TB according to the treatment strategies and prognosis: in medically treated, surgically treated and deceased patients groups. The same analyses were undertaken for drug-susceptible TB for comparison. The patients with MDR-TB or drug-susceptible TB were randomly selected from the TB cohort of Seoul National University Hospital, Seoul, South Korea. Results: Direct costs per person were US$4000 (US$2527-4841) in the medically treated group, US$17 457 (US$10 133-26 418) in the surgically treated group and US$33 362 (US$25 386-40 338) in the deceased group. Total costs per person were US$15 856 (US$10 752-38 421), US$47 159 (US$20 587-77 622) and US$478 357 (US$257 377-777 778), respectively. For the patients with drug-susceptible TB, the total cost ranged from US$1680 to US$7637 (median US$2166). Conclusions: The cost for the treatment of MDR-TB is seven to 22 times that of managing the drug-susceptible TB in South Korea. Considering the high cost, transmissibility and considerable fatality of MDR-TB, there is a need to provide specific separate funding for multidrug-resistant tuberculosis.

Original languageEnglish
Pages (from-to)793-798
Number of pages6
JournalRespirology
Volume11
Issue number6
DOIs
Publication statusPublished - 2006 Oct 1

Fingerprint

Multidrug-Resistant Tuberculosis
Republic of Korea
Health Care Costs
Costs and Cost Analysis
Pharmaceutical Preparations
Therapeutics
Mortality

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Kang, Y. A., Choi, Y. J., Cho, Y. J., Lee, S. M., Yoo, C. G., Kim, Y. W., ... Yim, J. J. (2006). Cost of treatment for multidrug-resistant tuberculosis in South Korea. Respirology, 11(6), 793-798. https://doi.org/10.1111/j.1440-1843.2006.00948.x
Kang, Young Ae ; Choi, Yong Jun ; Cho, Young Jae ; Lee, Sang Min ; Yoo, Chul Gyu ; Kim, Young Whan ; Han, Sung Koo ; Shim, Young Soo ; Yim, Jae Joon. / Cost of treatment for multidrug-resistant tuberculosis in South Korea. In: Respirology. 2006 ; Vol. 11, No. 6. pp. 793-798.
@article{94434a4990084518928fcf4e75e542ed,
title = "Cost of treatment for multidrug-resistant tuberculosis in South Korea",
abstract = "Objective and background: Costs associated with multidrug-resistant tuberculosis (MDR-TB) are higher than those associated with drug-susceptible TB because of the higher prices of second-line anti-TB drugs, the prolonged duration of treatment, greater productivity loss and higher mortality. The aim of this study was to estimate the cost of treatment for MDR-TB according to the treatment strategy and prognosis in South Korea. Methods: We estimated the direct (medical and non-medical) and indirect cost for the treatment of MDR-TB according to the treatment strategies and prognosis: in medically treated, surgically treated and deceased patients groups. The same analyses were undertaken for drug-susceptible TB for comparison. The patients with MDR-TB or drug-susceptible TB were randomly selected from the TB cohort of Seoul National University Hospital, Seoul, South Korea. Results: Direct costs per person were US$4000 (US$2527-4841) in the medically treated group, US$17 457 (US$10 133-26 418) in the surgically treated group and US$33 362 (US$25 386-40 338) in the deceased group. Total costs per person were US$15 856 (US$10 752-38 421), US$47 159 (US$20 587-77 622) and US$478 357 (US$257 377-777 778), respectively. For the patients with drug-susceptible TB, the total cost ranged from US$1680 to US$7637 (median US$2166). Conclusions: The cost for the treatment of MDR-TB is seven to 22 times that of managing the drug-susceptible TB in South Korea. Considering the high cost, transmissibility and considerable fatality of MDR-TB, there is a need to provide specific separate funding for multidrug-resistant tuberculosis.",
author = "Kang, {Young Ae} and Choi, {Yong Jun} and Cho, {Young Jae} and Lee, {Sang Min} and Yoo, {Chul Gyu} and Kim, {Young Whan} and Han, {Sung Koo} and Shim, {Young Soo} and Yim, {Jae Joon}",
year = "2006",
month = "10",
day = "1",
doi = "10.1111/j.1440-1843.2006.00948.x",
language = "English",
volume = "11",
pages = "793--798",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "6",

}

Kang, YA, Choi, YJ, Cho, YJ, Lee, SM, Yoo, CG, Kim, YW, Han, SK, Shim, YS & Yim, JJ 2006, 'Cost of treatment for multidrug-resistant tuberculosis in South Korea', Respirology, vol. 11, no. 6, pp. 793-798. https://doi.org/10.1111/j.1440-1843.2006.00948.x

Cost of treatment for multidrug-resistant tuberculosis in South Korea. / Kang, Young Ae; Choi, Yong Jun; Cho, Young Jae; Lee, Sang Min; Yoo, Chul Gyu; Kim, Young Whan; Han, Sung Koo; Shim, Young Soo; Yim, Jae Joon.

In: Respirology, Vol. 11, No. 6, 01.10.2006, p. 793-798.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost of treatment for multidrug-resistant tuberculosis in South Korea

AU - Kang, Young Ae

AU - Choi, Yong Jun

AU - Cho, Young Jae

AU - Lee, Sang Min

AU - Yoo, Chul Gyu

AU - Kim, Young Whan

AU - Han, Sung Koo

AU - Shim, Young Soo

AU - Yim, Jae Joon

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Objective and background: Costs associated with multidrug-resistant tuberculosis (MDR-TB) are higher than those associated with drug-susceptible TB because of the higher prices of second-line anti-TB drugs, the prolonged duration of treatment, greater productivity loss and higher mortality. The aim of this study was to estimate the cost of treatment for MDR-TB according to the treatment strategy and prognosis in South Korea. Methods: We estimated the direct (medical and non-medical) and indirect cost for the treatment of MDR-TB according to the treatment strategies and prognosis: in medically treated, surgically treated and deceased patients groups. The same analyses were undertaken for drug-susceptible TB for comparison. The patients with MDR-TB or drug-susceptible TB were randomly selected from the TB cohort of Seoul National University Hospital, Seoul, South Korea. Results: Direct costs per person were US$4000 (US$2527-4841) in the medically treated group, US$17 457 (US$10 133-26 418) in the surgically treated group and US$33 362 (US$25 386-40 338) in the deceased group. Total costs per person were US$15 856 (US$10 752-38 421), US$47 159 (US$20 587-77 622) and US$478 357 (US$257 377-777 778), respectively. For the patients with drug-susceptible TB, the total cost ranged from US$1680 to US$7637 (median US$2166). Conclusions: The cost for the treatment of MDR-TB is seven to 22 times that of managing the drug-susceptible TB in South Korea. Considering the high cost, transmissibility and considerable fatality of MDR-TB, there is a need to provide specific separate funding for multidrug-resistant tuberculosis.

AB - Objective and background: Costs associated with multidrug-resistant tuberculosis (MDR-TB) are higher than those associated with drug-susceptible TB because of the higher prices of second-line anti-TB drugs, the prolonged duration of treatment, greater productivity loss and higher mortality. The aim of this study was to estimate the cost of treatment for MDR-TB according to the treatment strategy and prognosis in South Korea. Methods: We estimated the direct (medical and non-medical) and indirect cost for the treatment of MDR-TB according to the treatment strategies and prognosis: in medically treated, surgically treated and deceased patients groups. The same analyses were undertaken for drug-susceptible TB for comparison. The patients with MDR-TB or drug-susceptible TB were randomly selected from the TB cohort of Seoul National University Hospital, Seoul, South Korea. Results: Direct costs per person were US$4000 (US$2527-4841) in the medically treated group, US$17 457 (US$10 133-26 418) in the surgically treated group and US$33 362 (US$25 386-40 338) in the deceased group. Total costs per person were US$15 856 (US$10 752-38 421), US$47 159 (US$20 587-77 622) and US$478 357 (US$257 377-777 778), respectively. For the patients with drug-susceptible TB, the total cost ranged from US$1680 to US$7637 (median US$2166). Conclusions: The cost for the treatment of MDR-TB is seven to 22 times that of managing the drug-susceptible TB in South Korea. Considering the high cost, transmissibility and considerable fatality of MDR-TB, there is a need to provide specific separate funding for multidrug-resistant tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=33750057967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750057967&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1843.2006.00948.x

DO - 10.1111/j.1440-1843.2006.00948.x

M3 - Article

C2 - 17052310

AN - SCOPUS:33750057967

VL - 11

SP - 793

EP - 798

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 6

ER -